| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Assaf-Harofeh Medical Center |
| Information provided by: | Assaf-Harofeh Medical Center |
| ClinicalTrials.gov Identifier: | NCT00497666 |
Purpose
Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy.
We decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.
| Condition | Intervention |
|
Diabetes Diabetic Nephropathy Renal Protection |
Drug: Rosiglitasone (retrospective observation) |
| MedlinePlus related topics: | Diabetes Diabetic Kidney Problems |
| ChemIDplus related topics: | Rosiglitazone Rosiglitazone Maleate |
| Study Type: | Observational |
| Study Design: | Cross-Sectional, Case Control, Retrospective Study |
| Official Title: | Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study |
| Study Start Date: | August 2007 |
| Estimated Study Completion Date: | December 2007 |
 |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Leonid S Feldman | +972-8-9779383 ext 9383 | leonidf@asaf.health.gov.il |
| Israel | |||||
| Clalit Health Cervices, Central District | Not yet recruiting | ||||
| Zerifin,, Israel, 70300 | |||||
| Contact: Leonid S Feldman +972-8-9779383 ext 9383 leonidf@asaf.health.gov.il | |||||
| Contact: Leonid S Feldman +972-8-9779383 ext 9383 leonidf@asaf.health.gov.il | |||||
| Sub-Investigator: Shlomo Vinker, MD | |||||
| Assaf-Harofeh Medical Center |
| Principal Investigator: | Leonid S Feldman | Nephrology Division, Assaf Harofeh Medical Center, Zerifin, |
| Principal Investigator: | Leonid S Feldman | Assaf-Harofeh Medical Center |
| Principal Investigator: | Leonid S Feldman | Nephrology Division, Assaf Harofeh Medical Center, Zerifin, |
More Information
| Study ID Numbers: | 346147Rosi |
| First Received: | July 6, 2007 |
| Last Updated: | July 6, 2007 |
| ClinicalTrials.gov Identifier: | NCT00497666 |
| Health Authority: | Israel: Ministry of Health |
|
|
|
|
|
